The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark,

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

At least one Woodward pharmacist is celebrating an action by Oklahoma Attorney General Gentner Drummond that could turn the tide for area pharmacists, some who are struggling to stay in

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs,

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts

In the lawsuit, AG Gentner Drummond outlined 200 individual prescription claims that were reimbursed below acquisition cost to 15 Oklahoma pharmacies.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for prescription drugs.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two

Attorney General Gentner Drummond sued CVS Caremark in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.

Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs. The lawsuit alleges CVS Caremark reimbursed Oklahoma pharmacies below the actual cost to acquire the drugs about 200 times between May and October 2024.